Zoledronic acid

Small molecule

Phase 3complete

Evidence outlook · registrational

HR+/HER2- Metastatic Breast Cancer: registrational trials complete

Its supporting mid-stage studies have completed. Its registrational studies have completed. Check News and the registry record for topline outcomes.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

This page stands for the molecule. Studies that name only the molecule, and no branded product, are listed here and are marked as studies of the molecule. A study of a branded product is on that product's page.

Phase 3 (87)
HR+/HER2- Metastatic Breast Cancer
NCT00556374 · Amgen
2006-12-18 – 2022-07-26 · Breast Cancer
What this study did
NCT00295646 · Austrian Breast & Colorectal Cancer Study Group
1999-06 – 2018-06-26 · Breast Cancer
What this study did
NCT00365105 · Radiation Therapy Oncology Group
2006-07-11 – 2017-02-27 · Breast Cancer, Lung Cancer, Metastatic Cancer, Pain, Prostate Cancer
What this study did
NCT00375505 · Novartis Pharmaceuticals
2005-10 – 2014-05 · Breast Cancer
What this study did
NCT00072020 · University of Sheffield
started 2003-08 · Breast Cancer, Metastatic Cancer
What this study did
NCT00320710 · Novartis Pharmaceuticals
2006-02 – 2013-07 · Breast Cancer
What this study did
NCT00712985 · Milton S. Hershey Medical Center
2005-09 – 2011-03 · Breast Cancer
What this study did
NCT00375427 · Novartis Pharmaceuticals
2006-02 – 2010-02 · Breast Cancer With Bone Metastasis
What this study did
NCT00372710 · Novartis
started 2002-08 · Breast Cancer With Bone Metastasis
What this study did
NCT00130494 · Spanish Breast Cancer Research Group
2002-08-29 – 2007-10-22 · Breast Cancer, Neoplasm Metastasis
What this study did
NCT00202059 · HealthPartners Institute
2003-06 – 2007-09 · Breast Cancer
What this study did
NCT00301886 · SWOG Cancer Research Network
2006-05 – 2006-05 · Breast Cancer, Hypercalcemia of Malignancy, Metastatic Cancer, Pain
What this study did
Other / comorbidity
NCT06221072 · Shanghai JMT-Bio Inc.
2024-04-05 – 2028-05-31 · Imaging Examination Shows at Least One Site With Bone Metastases From Soild Tumors
What this study did
NCT03295981 · St. Louis University
2018-05-03 – 2028-04 · Giant Cell Tumor of Bone
What this study did
NCT00470223 · UNICANCER
2007-03 – 2026-12 · Sarcoma
What this study did
NCT05866172 · Sun Yat-sen University
2023-05-10 – 2025-06-01 · Hepatocellular Carcinoma
What this study did
NCT00412022 · National Cancer Institute, Naples
2004-03 – 2024-11 · Breast Cancer
What this study did
NCT04303026 · Vestre Viken Hospital Trust
2020-03-02 – 2024-06-30 · Osteoarthritis, Hip
What this study did
NCT02595138 · Chinese Academy of Medical Sciences
2015-10 – 2023-12 · Triple Negative Breast Cancer
What this study did
NCT03951493 · Institut Cancerologie de l'Ouest
2020-06-23 – 2023-11-01 · Vertebral Metastasis
What this study did
NCT05164952 · Assiut University
2021-09-30 – 2023-09-30 · Use of Zoledronic Acid in Breast Cancer
What this study did
NCT03930992 · University of Guadalajara
2019-04-17 – 2022-10-31 · Secondary Osteoporosis
What this study did
NCT00127205 · SWOG Cancer Research Network
2005-07 – 2021-03-29 · Breast Cancer
What this study did
NCT02739555 · Assistance Publique - Hôpitaux de Paris
2016-06-23 – 2019-06-28 · Osteoid Osteoma
What this study did
NCT03040765 · Hamad Medical Corporation
2018-05-14 – 2019-04-08 · Thalassemia Majors (Beta-Thalassemia Major), Osteoporosis
What this study did
NCT00987636 · University Hospital Muenster
2009-10-01 – 2019-03-31 · Ewing's Sarcoma
What this study did
NCT01197300 · Novartis Pharmaceuticals
2010-10-25 – 2019-02-27 · Osteoporosis
What this study did
NCT02504008 · Axsome Therapeutics, Inc.
2015-07 – 2019-01 · Complex Regional Pain Syndrome, Reflex Sympathetic Dystrophy
What this study did
NCT02123264 · Carmen Gómez-Vaquero
2014-05 – 2018-06 · Arthritis, Rheumatoid
What this study did
NCT00799266 · Novartis Pharmaceuticals
2008-12-04 – 2018-03-05 · Osteoporosis
What this study did
NCT02622607 · Tang-Du Hospital
2013-01 – 2018-03 · Lung Cancer
What this study did
NCT01642901 · Thomas Jefferson University
2012-09 – 2018-03 · Spinal Cord Injury
What this study did
NCT00193856 · Trans Tasman Radiation Oncology Group
2003-10 – 2017-08 · Prostate Cancer
What this study did
NCT01802658 · Nantes University Hospital
2012-11 – 2016-12 · Bone Demineralization Lesions in the Injured Marrow
What this study did
NCT00982124 · Shriners Hospitals for Children
2007-10 – 2016-04 · Osteogenesis Imperfecta
What this study did
NCT01920568 · GlaxoSmithKline
2013-08 – 2016-04 · Fractures, Bone
What this study did
NCT00329797 · Radiation Therapy Oncology Group
2006-03 – 2014-11 · Osteoporosis, Prostate Cancer
What this study did
NCT00079001 · Alliance for Clinical Trials in Oncology
2004-01 – 2014-10 · Metastatic Cancer, Prostate Cancer
What this study did
NCT00685646 · Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
2008-05 – 2014-01 · Metastatic Cancer, Prostate Cancer
What this study did
NCT00512993 · GBG Forschungs GmbH
2004-12 – 2013-11 · Breast Cancer
What this study did
NCT02181101 · Ludwig-Maximilians - University of Munich
2005-09 – 2013-09 · Breast Neoplasms
What this study did
NCT01099436 · Borstkanker Onderzoek Groep
2010-04 – 2013-09 · Breast Cancer
What this study did
NCT00718861 · Novartis Pharmaceuticals
2008-05 – 2013-04 · Post-menopausal Osteoporosis
What this study did
NCT00215943 · H. Lee Moffitt Cancer Center and Research Institute
2003-06 – 2012-08 · Multiple Myeloma
What this study did
NCT00107263 · Alliance for Clinical Trials in Oncology
2005-01 – 2012-08 · Breast Cancer, Osteoporosis
What this study did
NCT01166178 · Novartis
2010-10 – 2012-06 · Osteoporosis, Multiple Sclerosis
What this study did
NCT00939900 · Seoul National University Bundang Hospital
2009-07 – 2012-06 · Avascular Necrosis of Femoral Head
What this study did
NCT00432458 · Mayo Clinic
2003-07 – 2012-04 · Multiple Myeloma and Plasma Cell Neoplasm
What this study did
Phase 2/3 (11)
HR+/HER2- Metastatic Breast Cancer
NCT01344967 · University Health Network, Toronto
2009-02 – 2011-12 · Metastatic Breast Cancer With Bone Involvement
What this study did
NCT00524849 · Fudan University
2006-11 – 2010-01 · Metastatic Breast Cancer, Bone Metastases
What this study did
Other / comorbidity
NCT00268476 · Medical Research Council
2005-07-08 – 2030-12 · Prostate Cancer
What this study did
NCT05106517 · Shenzhen People's Hospital
2021-09-08 – 2023-03-11 · Denosumab vs Zoledronate
What this study did
NCT01006395 · Austin Health
2011-01 – 2019-04 · Prostate Cancer
What this study did
NCT03289338 · Post Graduate Institute of Medical Education and Research, Chandigarh
2016-06-01 – 2018-12-31 · Charcot Arthropathy, Diabetes Complications
What this study did
NCT01426555 · Antonio Lazzari
2011-02 – 2015-02 · Osteoporosis
What this study did
NCT00297830 · Columbia University
2005-11 – 2014-01 · Heart Transplantation, Liver Transplantation, Bone Resorption
What this study did
NCT01654367 · Tianjin Medical University
2012-01 – 2013-12 · Breast Cancer
What this study did
NCT00691236 · Tata Memorial Hospital
2008-05 – 2013-08 · Osteosarcoma
What this study did
NCT01016093 · Tehran University of Medical Sciences
2009-11 – 2011-12 · Beta-Thalassemia, Bone Marrow Transplantation
What this study did
Phase 2 (72)
HR+/HER2- Metastatic Breast Cancer
NCT00903162 · Dana-Farber Cancer Institute
2009-05 – 2014-09 · Breast Cancer
What this study did
NCT00558272 · AstraZeneca
2008-02 – 2012-08 · Breast Cancer, Prostate Cancer, Bone Neoplasms
What this study did
NCT00760370 · Vejle Hospital
2008-12 – 2011-12 · Multiple Myeloma, Breast Cancer
What this study did
NCT00242203 · Washington University School of Medicine
2002-10 – 2011-05 · Breast Neoplasms
What this study did
NCT00525759 · Sheffield Teaching Hospitals NHS Foundation Trust
2007-07 – 2010-01 · Breast Cancer
What this study did
NCT00172068 · Novartis Pharmaceuticals
2002-01 – 2008-11 · Primary Breast Cancer
What this study did
NCT00213980 · University of Wisconsin, Madison
2000-01 – 2008-04 · Breast Cancer
What this study did
Other / comorbidity
NCT07668583 · Assistance Publique - Hôpitaux de Paris
2026-09-15 – 2029-12-31 · Osteomyelitis Chronic
What this study did
NCT03073785 · University of Nebraska
2017-03-23 – 2027-12 · Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage I Pancreatic Cancer AJCC v6 and v7, Stage IA Pancreatic Cancer AJCC v6 and v7, Stage IB Pancreatic Cancer AJCC v6 and v7, Stage II Pancreatic Cancer AJCC v6 and v7, Stage IIA Pancreatic Cancer AJCC v6 and v7, Stage IIB Pancreatic Cancer AJCC v6 and v7, Stage III Pancreatic Cancer AJCC v6 and v7, Stage IV Pancreatic Cancer AJCC v6 and v7
What this study did
NCT04608630 · Australian and New Zealand Intensive Care Research Centre
2021-07-15 – 2027-02-28 · Critical Illness, Osteoporosis
What this study did
NCT05595603 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2023-03 – 2026-12-01 · Giant Cell Tumor of Bone
What this study did
NCT03183557 · Shinshu University
2017-10-12 – 2025-06-08 · Osteoporosis
What this study did
NCT05080790 · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
2021-11-15 – 2025-01-20 · Leiomyosarcoma
What this study did
NCT04742010 · Stinus Gadegaard Hansen
2021-02-20 – 2024-08-12 · Bone Loss, Muscle Atrophy, Bariatric Surgery
What this study did
NCT04304755 · Oslo University Hospital
2021-10-25 – 2024-01-24 · Neovascular Age-related Macular Degeneration
What this study did
NCT00916747 · Boston Children's Hospital
2009-08 – 2023-12 · Progeria
What this study did
NCT03358017 · Mario Negri Institute for Pharmacological Research
2018-03-05 – 2023-07-25 · Triple Negative Breast Cancer
What this study did
NCT03396315 · Columbia University
2018-01-29 – 2023-06-09 · IOP, Osteoporosis
What this study did
NCT03336983 · Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
2017-12-01 – 2023-04-01 · Prostate Cancer, Bone Metastases
What this study did
NCT01679080 · University of Aarhus
2012-11 – 2021-06-01 · Osteogenesis Imperfecta
What this study did
NCT03118570 · Ultragenyx Pharmaceutical Inc
2017-09-11 – 2020-11-12 · Osteogenesis Imperfecta, Type I, Osteogenesis Imperfecta Type III, Osteogenesis Imperfecta Type IV
What this study did
NCT02325414 · Northwestern University
2015-02 – 2020-08-25 · Spinal Cord Injury, Acute Spinal Cord Injury, Bone Loss, Osteoporosis
What this study did
NCT02632903 · Children's Hospital of Eastern Ontario
2016-10 – 2018-08-20 · Osteoporosis, Osteonecrosis, Acute Lymphoblastic Leukemia
What this study did
NCT02347163 · Mario Negri Institute for Pharmacological Research
2015-02-03 – 2018-06-08 · Breast Cancer
What this study did
NCT01228318 · Emory University
2011-01 – 2017-04-13 · HIV Infection, Bone Loss, Osteopenia, Osteoporosis
What this study did
NCT02784652 · Severance Hospital
2014-06 – 2017-02-28 · Bone Metastasis, Gastrointestinal Cancer
What this study did
NCT02044978 · Per Aspenberg
2014-01 – 2017-01 · Pre-integration Failure of Dental Implant
What this study did
NCT01737216 · Hebei Tumor Hospital
2012-11 – 2016-12 · Lung Cancer
What this study did
NCT01788176 · University of Sao Paulo General Hospital
2013-12 – 2016-12 · Complex Regional Pain Syndromes
What this study did
NCT01204203 · University of Alabama at Birmingham
2009-06 – 2016-04 · Mesothelioma
What this study did
NCT00896532 · Amgen
2009-06-03 – 2016-02-18 · Low Bone Mineral Density, Postmenopausal Osteoporosis
What this study did
NCT00844480 · Thomas J. Schnitzer
2010-03 – 2016-01 · Bone Loss
What this study did
NCT00889590 · Leiden University Medical Center
2008-12 – 2015-07 · Giant Cell Tumor of Bone, Osteoclastoma
What this study did
NCT00081159 · M.D. Anderson Cancer Center
2004-07 – 2014-09 · Metastatic Cancer, Prostate Cancer
What this study did
NCT01194440 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2011-02 – 2014-01 · Ductal Carcinoma in Situ, Estrogen Receptor-positive Breast Cancer, Progesterone Receptor-positive Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
What this study did
NCT00781261 · University of Sydney
2009-08 – 2013-12 · Osteonecrosis
What this study did
NCT00295867 · University of California, San Francisco
2004-11-03 – 2013-12 · Breast Cancer
What this study did
NCT00731016 · Assistance Publique Hopitaux De Marseille
2008-10 – 2013-07 · Hutchinson-Gilford Progeria Syndrome
What this study did
NCT00554918 · University Hospital Birmingham
2005-02 – 2013-06 · Metastatic Cancer, Prostate Cancer
What this study did
NCT00582556 · University of Wisconsin, Madison
2003-04 – 2013-03 · Prostate Cancer
What this study did
NCT00577642 · Massachusetts General Hospital
2007-10 – 2012-12 · Multiple Myeloma
What this study did
NCT00301873 · Duke University
2006-05 – 2012-09 · Brain Tumors, Osteoporosis, Central Nervous System(CNS)Malignancies
What this study did
NCT01259193 · Fudan University
2010-10 – 2012-07 · Hepatocellular Carcinoma
What this study did
NCT01330238 · University of Oulu
2008-12 – 2012-03 · Low Back Pain
What this study did
NCT00321932 · University of Minnesota
2005-07 – 2012-03 · Leukemia, Lymphoma, Myelodysplastic Syndromes, Osteoporosis, Ovarian Cancer
What this study did
NCT00490698 · M.D. Anderson Cancer Center
2006-10 – 2012-01 · Kidney Cancer, Renal Cell Carcinoma
What this study did
NCT00305695 · Gynecologic Oncology Group
2005-11-28 – 2011-12-22 · Hereditary Breast and Ovarian Cancer Syndrome, Osteoporosis, Ovarian Carcinoma
What this study did
NCT01004510 · Peter Bushunow MD
2009-11 – 2011-04 · Malignant Pleural Effusion, Non Small Cell Lung Cancer
What this study did
NCT00559897 · Barbara Ann Karmanos Cancer Institute
2008-03 – 2011-04 · Lung Cancer, Metastatic Cancer
What this study did
Phase 1/2 (10)
HR+/HER2- Metastatic Breast Cancer
NCT00566618 · M.D. Anderson Cancer Center
2007-11-01 – 2020-11-17 · Breast Cancer, Bone Metastases
What this study did
NCT00060138 · Chugai Pharmaceutical
2002-11 – 2004-09 · Breast Cancer, Hypercalcemia of Malignancy, Metastatic Cancer, Pain
What this study did
Other / comorbidity
NCT06625190 · University of Florida
2026-02-11 – 2030-02 · Neuroblastoma, Rhabdomyosarcoma, Synovial Sarcoma, Peripheral Nerve Sheath Tumors, Clear Cell Sarcoma, Alveolar Soft Part Sarcoma, Desmoplastic Small Round Cell Tumor, Chordoma, Rhabdoid Tumor, Epithelioid Sarcoma, Myoepithelial Tumor, Osteosarcoma, Ewing Sarcoma, Wilms Tumor
What this study did
NCT07471516 · Institute of Hematology & Blood Diseases Hospital, China
2026-02-25 – 2027-08-12 · Congenital Dyserythropoietic Anemia (CDA)
What this study did
NCT06759064 · Qilu Hospital of Shandong University
2024-09-12 – 2026-09-01 · Cancer of Stomach, Adenocarcinoma, Ascites, Malignant
What this study did
NCT04279392 · University of Nebraska
2020-09-01 – 2022-12-30 · Bariatric Surgery Candidate, Bone Loss, Bone Resorption
What this study did
NCT01564121 · Nantes University Hospital
2006-01 – 2011-01 · Giant Cell Tumors of Bone
What this study did
NCT00588913 · Tokyo Women's Medical University
2006-01 – 2009-08 · Kidney Cancer, Metastatic Cancer
What this study did
NCT00482378 · Mayo Clinic
2005-03-21 – 2008-12-02 · Multiple Myeloma and Plasma Cell Neoplasm, Pain
What this study did
NCT00639392 · Virginia Commonwealth University
2007-06 – 2008-05 · Sickle Cell Disease
What this study did
Phase 1 (23)
HR+/HER2- Metastatic Breast Cancer
NCT00424983 · Novartis Pharmaceuticals
2006-11 – 2009-11 · Multiple Myeloma, Breast Cancer
What this study did
NCT00582920 · Memorial Sloan Kettering Cancer Center
2006-01 – 2008-10 · Osseous Lesions From Metastatic Breast Cancer
What this study did
NCT00264420 · The Cleveland Clinic
2005-12 – 2007-03 · Bone Metastases, Breast Cancer, Lung Cancer, Prostate Cancer
What this study did
NCT00051779 · Chugai Pharma USA
— · Breast Neoplasms, Breast Cancer, Metastasis
What this study did
Other / comorbidity
NCT07375290 · Children's Hospital Medical Center, Cincinnati
2026-07-17 – 2028-11 · Hematopoietic Stem Cell Transplantation
What this study did
NCT07741136 · University of Campinas, Brazil
2026-08-15 – 2028-08-15 · Chronic Kidney Disease, Osteoporosis, Dialysis
What this study did
NCT03173976 · Mohammed Milhem
2017-07-18 – 2028-05-01 · Chondrosarcoma
What this study did
NCT02508038 · University of Wisconsin, Madison
2016-02-12 – 2027-12 · Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Myelodysplastic Syndrome, Myeloproliferative Syndrome, Rhabdomyosarcoma, Ewing Sarcoma, Primitive Neuroectodermal Tumor, Osteosarcoma, Neuroblastoma
What this study did
NCT06513624 · National University Hospital, Singapore
2024-12-09 – 2027-06-30 · With MSS/pMMR Advanced, Platinum-resistant Ovarian Cancer
What this study did
NCT05053750 · M.D. Anderson Cancer Center
2021-12-14 – 2027-02-02 · Epithelial Ovarian, Fallopian Tube, Primary Peritoneal Cancer
What this study did
NCT05204836 · University of Calgary
2023-05-16 – 2025-07-03 · Anterior Cruciate Ligament Tear, Anterior Cruciate Ligament Rupture, Anterior Cruciate Ligament Injuries, Osteo Arthritis Knee
What this study did
NCT03862833 · Nantes University Hospital
2019-05-07 – 2023-08-29 · Hematopoietic Stem Cell Transplantation
What this study did
NCT00885326 · New Approaches to Neuroblastoma Therapy Consortium
2009-12 – 2019-12 · Neuroblastoma
What this study did
NCT01671774 · Astellas Pharma Global Development, Inc.
2012-10-16 – 2014-10-13 · CLDN18.2-positive Gastric Adenocarcinoma, CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction, CLDN18.2-positive Adenocarcinoma of Esophagus
What this study did
NCT01404702 · University of Alabama at Birmingham
2011-08 – 2014-08 · Neuroblastoma
What this study did
NCT00892242 · Washington University School of Medicine
2009-12 – 2013-04 · Adenocarcinoma
What this study did
NCT00742924 · Children's Oncology Group
2008-08 – 2012-04 · Sarcoma
What this study did
NCT00741377 · Novartis Pharmaceuticals
2009-01 – 2011-12 · Multiple Myeloma Bone Disease
What this study did
NCT00807963 · Halozyme Therapeutics
2008-12 – 2009-09-21 · Risk Factors for or a Diagnosis of Osteoporosis
What this study did
NCT00415779 · National Cancer Institute, Naples
2006-07 – 2009-07 · Metastatic Prostate Cancer
What this study did
NCT00258258 · Roswell Park Cancer Institute
2005-08 – 2009-03 · Multiple Myeloma and Plasma Cell Neoplasm
What this study did
NCT00278434 · University of California, San Francisco
2005-04 – 2008-07 · Cervical Cancer, Precancerous Condition
What this study did
NCT00004928 · Memorial Sloan Kettering Cancer Center
1999-10 – 2004-10 · Prostate Cancer
What this study did
Phase 4 (75)
HR+/HER2- Metastatic Breast Cancer
NCT02721433 · Ottawa Hospital Research Institute
2016-08 – 2020-04 · Breast Cancer, Prostate Cancer, Metastasis
What this study did
NCT01907880 · Ottawa Hospital Research Institute
2012-08 – 2016-01 · Breast Cancer
What this study did
NCT00333229 · Novartis Pharmaceuticals
2006-03 – 2013-12 · Primary Hormone Receptor Negative Breast Cancer in Premenopausal Women
What this study did
NCT01129336 · Novartis Pharmaceuticals
2010-06 – 2012-08 · First or Second Line HER2-negative Breast Cancer, Metastatic Disease Without Bone Metastasis
What this study did
NCT00912938 · Korean Breast Cancer Study Group
2007-12 – 2010-12 · Metastatic Breast Cancer
What this study did
NCT00334139 · Novartis Pharmaceuticals
2006-05 – 2009-07 · Prostate Cancer, Breast Cancer, Bone Metastasis
What this study did
NCT00172029 · Novartis
2003-04 – 2005-09 · Breast Cancer With Metastatic Bone Disease
What this study did
NCT00029224 · Novartis
2001-10 – 2002-11 · Breast Cancer, Multiple Myeloma, Prostate Cancer
What this study did
Other / comorbidity
NCT06762730 · Hadassah Medical Organization
2024-12-09 – 2032-12-01 · HIV Infected Individuals, Osteopenia
What this study did
NCT06059222 · University of Aarhus
2023-10-02 – 2032-08-31 · Osteoporosis
What this study did
NCT05091086 · National Taiwan University Hospital
2021-11-20 – 2030-12-31 · Osteoporosis, Bone Mineral Density
What this study did
NCT06767150 · University Hospital, Toulouse
2025-10-02 – 2030-10 · Postmenopausal Osteoporosis
What this study did
NCT06859580 · University of Aarhus
2025-03-01 – 2028-02-01 · Primary Hyperparathyroidism
What this study did
NCT05655013 · Aarhus University Hospital
2023-05-10 – 2027-02-01 · Osteoporosis, Postmenopausal
What this study did
NCT05666310 · Nami Safai Haeri
2023-02-14 – 2026-08-04 · Sarcopenia, Osteoporosis
What this study did
NCT05025293 · Lene Bergendal Solberg
2021-12-15 – 2026-06-11 · Hip Fractures, Osteoporosis
What this study did
NCT03924414 · California Pacific Medical Center Research Institute
2019-11-15 – 2026-02-28 · Parkinson Disease, Osteoporosis, Parkinsonism, Parkinson's Disease and Parkinsonism, Atypical Parkinsonism, Progressive Supranuclear Palsy, Multiple System Atrophy, Vascular Parkinsonism, Dementia With Lewy Bodies
What this study did
NCT05091099 · National Taiwan University Hospital
2022-01-10 – 2025-11-14 · Osteoporosis
What this study did
NCT05743179 · The University of Hong Kong
2022-12-05 – 2025-06 · Hip Fractures, Pneumonia
What this study did
NCT03664687 · Ottawa Hospital Research Institute
2018-10-31 – 2025-03-28 · Early-stage Breast Cancer
What this study did
NCT03735537 · University of Edinburgh
2016-11-01 – 2025-03-21 · Osteogenesis Imperfecta
What this study did
NCT04719650 · Peking University Third Hospital
2021-10 – 2024-11 · Postmenopausal Osteoporosis
What this study did
NCT06051344 · Toufiqe-E-Ealahi
2023-01-01 – 2023-12-31 · Primary Osteoarthritis
What this study did
NCT03868033 · National Taiwan University Hospital
2019-04-12 – 2023-12-31 · Osteoporosis
What this study did
NCT04085419 · University Medical Centre Ljubljana
2019-05-08 – 2023-05 · Primary Hyperparathyroidism, Osteoporosis
What this study did
NCT02286830 · Thomas Lund
2015-01 – 2023-02-16 · Multiple Myeloma
What this study did
NCT03932071 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2017-01-01 – 2023-01-01 · Lung Metastases, Tumor Necrosis
What this study did
NCT02480634 · Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
2019-06 – 2022-12 · Non-small Cell Lung Cancer, Bone Metastasis
What this study did
NCT04115397 · Karolinska Institutet
2020-01 – 2022-12 · Seropositive Muskuloskeletal Complaints
What this study did
NCT02589600 · Susan L. Greenspan
2016-01 – 2022-06-22 · Osteoporotic Fractures, Osteoporosis, Postmenopausal
What this study did
NCT03087851 · Aarhus University Hospital
2017-03-13 – 2020-08-01 · Osteoporosis
What this study did
NCT03158246 · Cttq
2017-06-01 – 2020-03-02 · Osteoporosis, Postmenopausal
What this study did
NCT02176382 · Massachusetts General Hospital
2014-08 – 2020-02 · Postmenopausal Osteoporosis
What this study did
NCT02333344 · Novartis Pharmaceuticals
2015-07-30 – 2020-01-28 · Prosthetic Fixation After Cementless Total Hip Arthroplasty
What this study did
NCT03424239 · Massachusetts General Hospital
2018-08-01 – 2020-01-01 · Bariatric Surgery Candidate
What this study did
NCT03576599 · Oslo University Hospital
2017-06-29 – 2019-06-26 · Stress Fracture Foot, Stress Fracture Ankle
What this study did
NCT02499237 · 424 General Military Hospital
2015-07 – 2018-11-26 · Postmenopausal Osteoporosis
What this study did
NCT01702415 · Papworth Hospital NHS Foundation Trust
2013-10 – 2015-12 · Cystic Fibrosis
What this study did
NCT02808988 · Ondokuz Mayıs University
2013-10 – 2015-11 · Chronic Periodontitis
What this study did
NCT01267279 · Spokane Joint Replacement Center
2005-01 – 2014-12 · Osteoporosis
What this study did
NCT01675089 · University of Sao Paulo General Hospital
2012-07 – 2014-05 · Renal Osteodystrophy
What this study did
NCT01087008 · PETHEMA Foundation
2010-04 – 2013-06-05 · Multiple Myeloma
What this study did
NCT01153425 · University of Pennsylvania
2008-07 – 2012-12 · Osteoporosis, Osteopenia
What this study did
NCT02042872 · James J. Peters Veterans Affairs Medical Center
2006-05 – 2012-07 · Disuse Osteoporosis
What this study did
NCT00622505 · Novartis Pharmaceuticals
2007-11-07 – 2012-04-03 · Multiple Myeloma
What this study did
NCT01310465 · Fudan University
2011-01 – 2012-04 · Image Changes of Lumbar Fusion, Bone Turnover Markers, Bone Mineral Density
What this study did
NCT00795483 · Germans Trias i Pujol Hospital
2009-11 – 2011-11 · HIV Infections
What this study did
Early phase / not applicable (25)
HR+/HER2- Metastatic Breast Cancer
NCT00458796 · University of Leeds
started 2006-03 · Breast Cancer, Hypercalcemia of Malignancy, Metastatic Cancer, Musculoskeletal Complications, Pain
What this study did
NCT00114270 · University of Virginia
2004-05 – 2007-06 · Breast Cancer, Osteoporosis
What this study did
Other / comorbidity
NCT07753317 · Cairo University
2026-08-07 – 2027-03-01 · Controlled Type 2 Diabetic Patients With Periodontitis
What this study did
NCT05904353 · University Hospital, Akershus
2024-01-01 – 2026-12 · Hip Fractures, Osteoporosis, Zoledronic Acid, Ambulant Nurse, Case Manager
What this study did
NCT07546058 · Latakia University
2024-12-01 – 2026-02-03 · Orthodontic Appliance Complication
What this study did
NCT06876636 · Xijing Hospital
2025-03-10 – 2025-12 · Breast Cancer Metastatic
What this study did
NCT04652128 · Yonsei University
2019-07-15 – 2023-02 · Stroke
What this study did
NCT02069340 · University of Southern California
2016-06 – 2021-06 · Malignant Neoplasm, Musculoskeletal Complications
What this study did
NCT02451462 · Stanford University
2015-09 – 2018-09 · Hematopoietic Stem Cell Transplant, Bone Marrow Transplant
What this study did
NCT01772719 · University of Louisville
2012-08 – 2016-11 · Multiple Myeloma
What this study did
NCT00436917 · Mayo Clinic
2006-04 – 2016-05-09 · Breast Cancer, Osteoporosis
What this study did
NCT02721940 · Chinese PLA General Hospital
2012-02 – 2016-05 · Osteonecrosis
What this study did
NCT01205646 · Barbara Ann Karmanos Cancer Institute
2010-09 – 2015-08 · Prostate Cancer
What this study did
NCT01409811 · City of Hope Medical Center
2013-02-20 – 2015-02-01 · Estrogen Receptor-positive Breast Cancer, Invasive Ductal Breast Carcinoma, Progesterone Receptor-positive Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer
What this study did
NCT00580047 · University of Nebraska
2003-12-01 – 2014-07-29 · Renal Insufficiency
What this study did
NCT00558012 · University of Pittsburgh
2007-12 – 2014-02 · Osteoporosis, Bone Loss, Fragility Fractures
What this study did
NCT01623908 · First Affiliated Hospital, Sun Yat-Sen University
2011-07 – 2013-06 · Breast Neoplasms, Bone Loss
What this study did
NCT01572545 · Aristotle University Of Thessaloniki
2012-04 – 2013-01 · Postmenopausal Osteoporosis
What this study did
NCT00489905 · Hospital Authority, Hong Kong
2005-04 – 2008-05 · Prostatic Neoplasms, Bone Density
What this study did
NCT00361595 · The Cleveland Clinic
2006-08 – 2008-04 · Osteoporosis
What this study did
NCT00087659 · Novartis Pharmaceuticals
2003-12 – 2007-05 · Prostate Cancer
What this study did
NCT00126386 · Alberta Health services
2004-01 – 2006-09 · Cancer, Hypercalcemia, Pain
What this study did
NCT00302484 · Medical University of Vienna
started 2002-04 · Osteoporosis, Liver Transplantation
What this study did
NCT00520052 · Wirral University Teaching Hospital NHS Trust
2003-08 – 2005-08 · Osteoporosis
What this study did
Used as active comparator (23)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (11)
HR+/HER2- Metastatic Breast Cancer
NCT00326820 · Wales Cancer Trials Unit
2006-01 – 2015-10 · Breast Cancer, Hypercalcemia of Malignancy, Metastatic Cancer
What this study did
NCT00321464 · Amgen
2006-04-01 – 2012-04-04 · Bone Metastases
What this study did
Other / comorbidity
NCT06533865 · Massachusetts General Hospital
2025-03-19 – 2029-04 · FHA (Functional Hypothalamic Amenorrhea)
What this study did
NCT05638399 · Shenzhen People's Hospital
2020-01-15 – 2023-02-28 · Osteopenia, Lumbar Spondylolisthesis
What this study did
NCT04034199 · Kwong Wah Hospital
2019-08-15 – 2021-03-31 · Idiopathic Inflammatory Myopathies, Osteoporosis, Osteopenia
What this study did
NCT01345019 · Amgen
2012-05-17 – 2019-03-29 · Cancer, Hematologic Malignancies, Multiple Myeloma, Oncology, Bone Metastases, Multiple Myeloma Bone Lesions
What this study did
NCT00321620 · Amgen
2006-04-01 – 2012-02-24 · Bone Metastases
What this study did
NCT00330759 · Amgen
2006-06-01 – 2011-10-01 · Bone Metastases
What this study did
NCT02739594 · Hoffmann-La Roche
2006-02 – 2009-04 · Multiple Myeloma
What this study did
NCT00099177 · Hoffmann-La Roche
2005-08 – 2007-12 · Pain, Bone Neoplasm, Neoplasm Metastasis
What this study did
NCT00099203 · Hoffmann-La Roche
2005-07 – 2007-12 · Pain, Bone Neoplasm, Neoplasm Metastasis
What this study did
Phase 2 (3)
Other / comorbidity
NCT04325776 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2020-09-24 – 2021-11 · Bone Metastatic Non-small Cell Lung Cancer
What this study did
NCT02632916 · Children's Hospital of Eastern Ontario
2016-08 – 2020-02-03 · Osteoporosis
What this study did
NCT01951586 · Amgen
2013-12-31 – 2017-11-28 · Non-Small Cell Lung Cancer
What this study did
Phase 1/2 (1)
HR+/HER2- Metastatic Breast Cancer
NCT06374459 · Washington University School of Medicine
2025-01-30 – 2032-05-31 · Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer
What this study did
Phase 1 (1)
Other / comorbidity
NCT01721993 · Thar Pharmaceuticals, Inc
2013-01 – 2014-08 · Healthy Postmenopausal Women
What this study did
Phase 4 (7)
Other / comorbidity
NCT07772609 · Sahlgrenska University Hospital
2027-01-11 – 2031-12-31 · Osteoporosis in Post-menopausal Women
What this study did
NCT07406685 · National Taiwan University Hospital
2026-08-20 – 2030-10-31 · Postmenopausal Osteoporosis, Postmenopausal Osteopenia, Primary Osteoporosis, Osteoporosis
What this study did
NCT06118905 · Chrissy Kistler
2024-02-08 – 2029-03-31 · Osteoporosis
What this study did
NCT04597931 · Sheba Medical Center
2020-11-01 – 2023-11-15 · Osteoporosis Fracture, Spinal Cord Injuries
What this study did
NCT05598606 · Shenzhen People's Hospital
2021-01-12 – 2023-01-14 · Denosumab Allergy, Zoledronic Acid Allergy
What this study did
NCT01732770 · Amgen
2012-11-07 – 2015-01-07 · Post Menopausal Osteoporosis
What this study did
NCT00927186 · Eli Lilly and Company
2009-07 – 2012-04 · Osteoporosis, Post-menopausal
What this study did
Appears in other studies (12)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (2)
Other / comorbidity
NCT04779216 · Karen Klahr Miller, MD
2021-09-20 – 2025-11-17 · Bone Density, Low, Bone Loss, Anorexia Nervosa, Eating Disorders
What this study did
NCT02516423 · Alliance for Clinical Trials in Oncology
2016-11-29 – 2025-09-30 · Solitary Osseous Plasmacytoma
What this study did
Phase 2 (2)
HR+/HER2- Metastatic Breast Cancer
NCT01067989 · HaEmek Medical Center, Israel
2010-03 – 2014-04 · Chemotherapy, Breast Cancer, Metastatic
What this study did
Other / comorbidity
NCT01332617 · University of Louisville
2011-04 – 2019-02 · Myeloma
What this study did
Phase 1 (1)
Other / comorbidity
NCT05400603 · Emory University
2023-11-06 – 2026-12 · Neuroblastoma, Refractory Neuroblastoma, Relapsed Neuroblastoma, Relapsed Osteosarcoma, Refractory Osteosarcoma
What this study did
Phase 4 (4)
Other / comorbidity
NCT07281586 · National Taiwan University Hospital
2026-01-01 – 2028-12-31 · Osteoporosis
What this study did
NCT05058976 · Susan L. Greenspan
2021-09-15 – 2027-03-31 · Osteoporosis, Osteoporosis, Postmenopausal, Osteoporosis Fracture
What this study did
NCT06135298 · Aksaray University
2023-12-01 – 2026-01-15 · Trochanteric Fracture of Femur, Osteoporotic Fracture of Femur, Hip Fractures, Bone Density, Low
What this study did
NCT04087096 · Massachusetts General Hospital
2020-08-24 – 2024-08-06 · Bariatric Surgery Candidate, Bone Loss
What this study did
Early phase / not applicable (3)
HR+/HER2- Metastatic Breast Cancer
NCT07823751 · Universitas Indonesia
2021-04-10 – 2026-06-20 · Breast Cancer With Bone Metastasis
What this study did
Other / comorbidity
NCT05906056 · University of Ioannina
2023-05-12 – 2027-03-25 · Traumatic Brain Injury, Spinal Cord Injuries, Stroke
What this study did
NCT04498715 · Lithuanian University of Health Sciences
2021-06-01 – 2024-12 · Trochanteric Fracture of Femur
What this study did

Competitive landscape

2 other tracked programmes target this mechanism, 2 of them ahead of this one.

This drug's own stage for HR+/HER2- Metastatic Breast Cancer: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Zoledronic Acid: this drugPhase 3Small moleculeFarnesyl pyrophosphate synthase (FPPS)not yet gradedNo reviewed efficacy summary in this indication
Abemaciclib (Verzenio)ApprovedSmall moleculeCDK4 and CDK6Reliable signal
NCT02107703: Progression-Free Survival (PFS) (From Date of Randomization until Disease Progression or Death Due to Any Cause (Up To 31 Months)): Abemaciclib + Fulvestrant 16.4 Months (95% CI 14.4 to 19.3) vs Placebo + Fulvestrant 9.3 Months (95% CI 7.4 to 11.4)
NCT02102490: Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR]) (From Date of First Dose until Disease Progression or Death Due to Any Cause (Up To 14 Months)): Abemaciclib 19.7% (95% CI 13.3 to 27.5)
Alpelisib (BYL719)ApprovedSmall moleculePI3K-alphaReliable signal
NCT02437318: Progression-free Survival (PFS) Per Investigator Assessment in the PIK3CA Mutant Cohort (Once approximately 243 PFS events in the PIK3CA mutant cohort had been observed, up to 33.3 months): PIK3CA Mutant Cohort by Tumor Tissue: Alpelisib + Fulvestrant 11 Months (95% CI 7.49 to 14.52) vs PIK3CA Mutant Cohort by Tumor Tissue: Placebo + Fulvestrant 5.7 Months (95% CI 3.65 to 7.36)
AnastrozoleApprovedSmall moleculeAromatasenot yet graded
NCT00291759: Recurrence-free survival, 2yr tamoxifen then 3yr anastrozole vs 5yr tamoxifen: HR 0.80 (95% CI 0.63-1.01), P=.06 (not statistically significant) missed phase 3 result · pivotal pending
NCT00300508: At a median follow-up of 62.3 months, women who received anastrozole (n=387) had a statistically significantly reduced risk of recurrence (locoregional recurrence, contralateral breast cancer or distant metastasis) versus women who received no further treatment (n=469): hazard ratio 0.62 (95% CI 0.40-0.96), P=.031. phase 3 result · pivotal pending
Camizestrant (Etcamah)ApprovedSmall moleculeEstrogen receptorReliable signal
NCT04964934: SERENA-6 (NCT04964934), primary endpoint PFS: median PFS 16.0 months (camizestrant + CDK4/6i) vs 9.2 months (aromatase inhibitor + CDK4/6i); HR 0.44 (95% CI 0.31-0.60); p<0.00001
NCT04588298: Percentage Change From Baseline in Estrogen Receptor (ER) Expression Between Pre- and On-treatment Tumour Samples (Primary Analysis) (Baseline (Screening Day -21 to 1) to Biopsy day (Days 5-7 [Stage 1 and 2] or Days 12-15 [Stage 3])): AZD9833 75 mg (Stage 1 + 2) -62.7% (95% CI -67.46--57.93) vs AZD9833 150 mg (Stage 1 + 2) -62.8% (95% CI -67.13--58.43) vs AZD9833 300 mg (Stage 2) -67.1% (95% CI -74.49--59.74) vs AZD9833 75 mg (Stage 3) -66.9% (95% CI -72.34--61.46) vs AZD9833 150 mg (Stage 3) -65.0% (95% CI -70.27--59.81)
Capecitabine
ApprovedUS marketing discontinued
Small moleculeFluoropyrimidine (antimetabolite)not yet gradedNo reviewed efficacy summary in this indication
CapivasertibApprovedSmall moleculeAKT (inhibitor)Reliable signal
NCT04305496: Progression Free Survival: Overall Population (Months) in the Global Cohort (Assessed every 8 weeks for the first 18 months and every 12 weeks thereafter, from randomization to radiological progression.): Capivasertib + Fulvestrant (Global + China Cohort) 7.2 Months (95% CI 5.5 to 7.4) vs Placebo + Fulvestrant (Global + China Cohort) 3.6 Months (95% CI 2.8 to 3.7)
NCT01625286: Progression-free survival, Part B (randomized vs placebo + paclitaxel): median 10.9 months (95% CI 8.3 to 12.4) with capivasertib vs 8.4 months (95% CI 8.2 to 10.8) with placebo; HR 0.80 (95% CI 0.60 to 1.06), p=0.308 (CT.gov posted results). missed
Datopotamab DeruxtecanApprovedAntibody–drug conjugateTROP2Partial signal
NCT05104866: Progression-Free Survival (On-study tumor assessments occur every 6 weeks then every 9 weeks until disease progression, death or withdrawal of consent assessed up to data cut-off (17Jul2023) to a maximum of approximately 21 months): Dato-DXd 6.9 Months (95% CI 5.7 to 7.4) vs Investigator's Choice of Chemotherapy (ICC) 4.9 Months (95% CI 4.2 to 5.5)
Docetaxel (Taxotere)ApprovedSmall moleculeMicrotubules (tubulin)Partial signal
NCT00002662: ORR (the registered first objective) 32% vs 25% (P=.10); OS 15.4 vs 12.7 months (P=.03) and TTP 5.7 vs 3.6 months (P<.0001) favored docetaxel. missed
ElacestrantApprovedSmall moleculeEstrogen receptorPartial signal
NCT03778931: Progression-free Survival in ESR1-mut Participants (From Date of Randomization until Disease Progression or Death Due to Any Cause (up to 12 Months)): Elacestrant 3.78 months (95% CI 2.17 to 7.26) vs Standard of Care (SoC) 1.87 months (95% CI 1.87 to 2.14)
Eribulin MesylateApprovedSmall moleculeTubulin / microtubulesPartial signal
NCT02225470: Progression-Free Survival, eribulin vs vinorelbine (independent tumor assessment): HR 0.80 (95% CI 0.65-0.98, P=0.036) in favor of eribulin; median PFS 2.8 months in both arms
NCT00337103: Co-primary endpoints, eribulin (n=554) vs capecitabine (n=548): overall survival median 15.9 vs 14.5 months, HR 0.88 (95% CI 0.77 to 1.00), P = .056; progression-free survival median 4.1 vs 4.2 months, HR 1.08 (95% CI 0.93 to 1.25), P = .30 (Kaufman et al., J Clin Oncol 2015). missed
EverolimusApprovedSmall moleculemTOR kinase, mTOR (mTORC1) (inhibitor)Weak signal
NCT02511639: Median progression-free survival: 9.9 months (everolimus + aromatase inhibitor) vs 7.2 months (aromatase inhibitor alone); HR 0.764 (95% CI 0.501-1.164)
NCT00863655: Progression-free Survival (PFS) Based on Local Radiology Review of Tumor Assessments. (date of randomization to the date of first documented tumor progression or death from any cause, whichever occurs first, reported between day of first patient randomized up to about 19 months): Everolimus + Exemestane 6.93 months (95% CI 6.44 to 8.05) vs Placebo + Exemestane 2.83 months (95% CI 2.76 to 4.14)
ExemestaneApprovedSmall moleculeAromatasePartial signal
NCT00002777: Objective response rate: 46% exemestane vs 31% tamoxifen (odds ratio 1.85, 95% CI 1.21-2.82, P=.005). Median progression-free survival (the trial's primary endpoint): 9.9 months exemestane vs 5.8 months tamoxifen; long-term log-rank P=.121 (not statistically significant). missed
Fulvestrant (Faslodex)ApprovedSmall moleculeEstrogen receptorPartial signal
NCT01602380: Comparison of Progression-Free Survival (PFS) in Patients Treated With Fulvestrant With Those Treated With Anastrozole (Baseline RECIST 1.1 assessments (Day 0) and then every 12 weeks until the earliest of disease progression evident, patient dies or has surgery/radiotherapy for their disease (up to approximately 38 months)): Fulvestrant 500 mg 16.6 Months (95% CI 13.83 to 20.99) vs Anastrozole 1 mg 13.8 Months (95% CI 11.99 to 16.59)
NCT00099437: Progression-free survival: fulvestrant 500 mg (n=362) vs 250 mg (n=374), HR 0.80 (95% CI 0.68 to 0.94), P = .006; CT.gov median time to progression 6.5 vs 5.5 months (Di Leo et al., J Clin Oncol 2010).
Gedatolisib (Revtorpyk)ApprovedSmall moleculePI3K (class I isoforms) and mTORC1/mTORC2Partial signal
NCT05501886: VIKTORIA-1 (NCT05501886), PIK3CA wild-type cohort, primary endpoint PFS: gedatolisib+fulvestrant+palbociclib (triplet) median PFS 9.3 months vs fulvestrant alone 2.0 months, HR 0.24 (95% CI 0.17-0.35), p<0.0001; gedatolisib+fulvestrant (doublet) median PFS 7.4 months, HR 0.33 (95% CI 0.24-0.48), p<0.0001.
Gemcitabine
ApprovedUS marketing discontinued
Small moleculeribonucleotide reductase / DNA polymerase (dCTP competition)Weak signal
NCT00128310: Median progression-free survival: 6.0 months (gemcitabine + vinorelbine) vs 4.0 months (vinorelbine alone); hazard ratio 0.66 (p=0.0028). Overall survival not significantly different (15.9 vs 16.4 months, p=0.8046)
NCT00006459: Eli Lilly's pivotal phase III global registration trial of gemcitabine + paclitaxel vs paclitaxel alone in anthracycline-pretreated advanced breast cancer, matching this listing's title/sponsor. Primary endpoint (overall survival): 18.6 vs 15.8 months, HR 0.78 (95% CI 0.64-0.96), p=0.0187, favoring the gemcitabine combination.
GoserelinApprovedPeptideGnRH receptor (agonist)not yet gradedNo reviewed efficacy summary in this indication
Imlunestrant (Inluriyo)ApprovedSmall moleculeEstrogen receptorPartial signal
NCT04975308: Investigator-assessed PFS. ESR1-mutated population: imlunestrant 5.49 vs 3.84 months with standard endocrine therapy, HR 0.617 (95% CI 0.464 to 0.821), p=0.0008. All patients: 5.55 vs 5.52 months, HR 0.867 (95% CI 0.724 to 1.039), p=0.1158 (not significant). Imlunestrant plus abemaciclib vs imlunestrant: 9.36 vs 5.49 months, HR 0.569 (95% CI 0.441 to 0.733), p<0.0001
Inavolisib (Itovebi)ApprovedSmall moleculePI3K-alphaReliable signal
NCT04191499: Progression-Free Survival (PFS) (Up to 3.7 years): Inavo+Palbo+Fulv 15 months (95% CI 11.3 to 20.5) vs Pbo+Palbo+Fulv 7.3 months (95% CI 5.6 to 9.3)
IxabepiloneApprovedSmall moleculeMicrotubules (tubulin)Partial signalFeatured results are non-efficacy only in this race
LetrozoleApprovedSmall moleculeAromatasenot yet graded
NCT00003140: Estimated 4-year disease-free survival: letrozole 93% vs placebo 87% (75 vs 132 recurrences/new cancers out of 5187 enrolled); P<=0.001 phase 3 result · pivotal pending
NCT00004205: Disease-free survival (primary endpoint), letrozole vs tamoxifen: 5-year DFS 84.0% vs 81.4%; HR 0.81 (95% CI 0.70-0.93), P=0.003, at median follow-up 25.8 months (351 vs 428 events; N=8010). phase 3 result · pivotal pending
Nab-PaclitaxelApprovedSmall moleculeMicrotubulesPartial signal
NCT00785291: Progression Free Survival (Time from randomization to progression or death due to any cause, whichever occurs first (up to 5 years)): Arm B (Nab-paclitaxel) 9.3 months (95% CI 8.15 to 10.45) vs Arm A (Paclitaxel) 10.97 months (95% CI 9.79 to 12.42) vs Arm C (Ixabepilone) 7.36 months (95% CI 6.21 to 8.18) missed
OlaparibApprovedSmall moleculePARPPartial signal
NCT02000622: Progression-free Survival (PFS) Using Blinded Independent Central Review (BICR) According to Modified Response Evaluation Criteria In Solid Tumours (RECIST v1.1) (Radiological scans performed at baseline then every ~6 weeks up to 24 weeks, then every ~ 12 weeks thereafter until objective radiological disease progression. Assessed up to a maximum of 30 months.): Olaparib 300 mg bd 7 Months (95% CI 5.7 to 8.3) vs Chemotherapy 4.2 Months (95% CI 2.8 to 4.3)
NCT03286842: Progression-free Survival (PFS) in Real-world Setting in Germline BRCA Mutated Participants (At every visit until the earliest of disease progression, death or end of study (up to 3 years)): Olaparib gBRCAm Cohort 8.18 months (95% CI 6.97 to 9.17)
Palbociclib (Ibrance)ApprovedSmall moleculeCDK4 and CDK6Reliable signal
NCT02297438: Progression-Free Survival (PFS) Based on Investigator's Assessment: Up to Primary Completion Date (Randomization up to 65 months): Palbociclib + Letrozole 21.5 Months (95% CI 16.6 to 24.9) vs Placebo + Letrozole 13.9 Months (95% CI 13.7 to 16.6)
NCT01740427: Progression-Free Survival (PFS) as Assessed by the Investigator (From randomization date to date of first documentation of progression or death (up to approximately 2.5 years)): Palbociclib Plus Letrozole 24.8 Months vs Placebo Plus Letrozole 14.5 Months (95% CI 12.9 to 17.1)
RibociclibApprovedSmall moleculeCDK4 and CDK6Reliable signal
NCT02422615: Progression Free Survival (PFS) Per Investigator Assessment (From randomization to first documented progression or death, assessed up to approximately 26 months): Ribociclib + Fulvestrant 20.5 Months (95% CI 18.5 to 23.5) vs Placebo + Fulvestrant 12.8 Months (95% CI 10.9 to 16.3)
NCT02278120: Progression Free Survival (PFS) by Investigator Assessment (From randomization to first documented progression or death, assessed up to approximately 29 months): Ribociclib + NSAI/Tamoxifen + Goserelin 23.8 Months vs Placebo + NSAI/Tamoxifen+ Goserelin 13 Months (95% CI 11 to 16.4)
Sacituzumab GovitecanApprovedAntibody–drug conjugateTROP2Partial signal
NCT03901339: Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment (Up to 42.8 months): Sacituzumab Govitecan 5.5 months (95% CI 4.2 to 6.9) vs Treatment of Physician's Choice (TPC) 4 months (95% CI 3 to 4.4)
TalazoparibApprovedSmall moleculePARPPartial signal
NCT01945775: Progression-Free Survival (PFS): Independent Radiological Facility (IRF) Assessment (Baseline until radiologic progressive disease or death due to any cause (up to maximum duration of 36.9 months)): Talazoparib 8.6 months (95% CI 7.2 to 9.3) vs Physician's Choice Treatment 5.6 months (95% CI 4.2 to 6.7)
Tamoxifen (Soltamox)ApprovedSmall moleculeEstrogen receptornot yet gradedNo reviewed efficacy summary in this indication
Trastuzumab DeruxtecanApprovedAntibody–drug conjugateHER2Partial signal
NCT04494425: Progression-Free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Low Population (Response evaluations performed at screening, every 6 weeks (q6w) ± 1 week from randomization for 48 weeks, and then every 9 weeks (q9w) ± 1 week, starting at Week 48 until PD, up to PCD of 18 March 2024 (maximum of approximately 43.85 months)): T-DXd 13.2 months (95% CI 11.4 to 15.2) | Chemotherapy 8.1 months (95% CI 7 to 9)
NCT03734029: Progression-free Survival (PFS) Based on Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer (From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years): Trastuzumab Deruxtecan (T-DXd) 10.1 months (95% CI 9.5 to 11.5) | Physician's Choice 5.4 months (95% CI 4.4 to 7.1)
Vepdegestrant (Veppanu)ApprovedSmall moleculeEstrogen receptorPartial signal
NCT05654623: PFS by BICR vs fulvestrant: ESR1-mutation population median 5.0 vs 2.1 months, hazard ratio 0.58 (95% CI 0.43 to 0.78), P<0.001; all randomized patients 3.8 vs 3.6 months, hazard ratio 0.83 (95% CI 0.69 to 1.01), P=0.07 (NEJM 2025).
NCT04072952: Clinical benefit rate 38% (total n=71), the trial's primary endpoint (VERITAC expansion); CBR 51.2% in ESR1-mutant patients (n=41)
Zoledronic Acid (Reclast)
Approved(overall)
Small moleculeFarnesyl pyrophosphate synthase (FPPS)
not yet graded(overall)
No reviewed efficacy summary in this indication
Zoledronic Acid (Zometa)
Approved(overall)
Small moleculeFarnesyl pyrophosphate synthase (FPPS)
not yet graded(overall)
No reviewed efficacy summary in this indication
AfuresertibPhase 3Small moleculeAKT (inhibitor)Partial signal
NCT04851613: Primary endpoint, progression-free survival: median 7.6 months with afuresertib plus fulvestrant vs 2.0 months with placebo plus fulvestrant (sponsor topline, 2026-04-15).
Anbenitamab RepodatecanPhase 3Antibody–drug conjugateHER2 (biparatopic — extracellular domains II and IV)not yet gradedNo reviewed efficacy summary in this indication
AtirmociclibPhase 3Small moleculeCDK4Partial signal
NCT06465368: Percentage of Participants With Complete Cell Cycle Arrest (CCCA) at Day 14 (Day 14): PF-07220060 + Letrozole 88.2% (95% CI 76.6-94.5) vs Letrozole Alone 17.9% (95% CI 10.0-29.8)
BEBT-209Phase 3Small moleculeCDK4 (selective)not yet gradedNo reviewed efficacy summary in this indication
Beruzatatug PelitecanPhase 3Antibody–drug conjugateHER3not yet gradedNo reviewed efficacy summary in this indication
BGB-43395Phase 3Small moleculeCDK4not yet gradedNo reviewed efficacy summary in this indication
BireociclibPhase 3Small moleculeCDK2/4/6Reliable signal
NCT05077449: BRIGHT-2 (NCT05077449), primary endpoint median PFS: bireociclib (XZP-3287) + fulvestrant 14.7 months vs placebo + fulvestrant 7.3 months; HR 0.54 (95% CI 0.40-0.74); p<0.001
ChidamidePhase 3Small moleculeHDACReliable signal
NCT02482753: Investigator-assessed median PFS: 7.4 months (95% CI 5.5-9.2) chidamide+exemestane vs 3.8 months (95% CI 3.7-5.5) placebo+exemestane; hazard ratio 0.755, p=0.0336
CulmerciclibPhase 3Small moleculeCDK2/CDK4/CDK6, CDK2/4/6/CDK4Partial signal
NCT05375461: Median investigator-assessed PFS: 16.6 months (culmerciclib + fulvestrant) vs 7.5 months (placebo + fulvestrant); HR 0.36 (95% CI 0.26-0.51), P<0.001, meeting the primary endpoint.
DalpiciclibPhase 3Small moleculeCDK4 and CDK6not yet gradedNo reviewed efficacy summary in this indication
Denosumab (Xgeva)Phase 3Monoclonal antibodyRANKLnot yet gradedNo reviewed efficacy summary in this indication
Disitamab VedotinPhase 3Antibody–drug conjugateHER2Partial signal
NCT03052634: Confirmed ORR at 2.0 mg/kg Q2W: 42.9% (9/21) in HER2-overexpression and 33.3% (22/66) in HER2-low advanced breast cancer; median PFS 5.7 and 5.1 months
GiredestrantPhase 3Small moleculeEstrogen receptorPartial signal
NCT04546009: persevERA (NCT04546009), primary endpoint investigator-assessed PFS: giredestrant plus palbociclib median PFS 33.1 months vs letrozole plus palbociclib 28.2 months; HR 0.89 (95% CI 0.76-1.05); p=.1553. missed
HRS-6209Phase 3Small moleculeCDK4not yet gradedNo reviewed efficacy summary in this indication
HRS-8080Phase 3Small moleculeEstrogen receptor (degrader)not yet gradedNo reviewed efficacy summary in this indication
Izalontamab BrengitecanPhase 3Antibody–drug conjugateEGFR + HER3not yet gradedNo reviewed efficacy summary in this indication
JS105Phase 3Small moleculePI3K-alpha (mutant-selective)not yet gradedNo reviewed efficacy summary in this indication
NTQ1062Phase 3Small moleculeAKT (inhibitor)not yet gradedNo reviewed efficacy summary in this indication
PalazestrantPhase 3Small moleculeEstrogen receptorWeak signalNo reviewed efficacy summary in this indication
Patritumab DeruxtecanPhase 3Antibody–drug conjugateHER3Weak signalNo reviewed efficacy summary in this indication
PembrolizumabPhase 3Monoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
PrifetrastatPhase 3Small moleculeKAT6A / KAT6Bnot yet gradedNo reviewed efficacy summary in this indication
Sacituzumab TirumotecanPhase 3Antibody–drug conjugateTROP2not yet gradedNo reviewed efficacy summary in this indication
SaruparibPhase 3Small moleculePARP1 inhibitor (next-gen)not yet gradedNo reviewed efficacy summary in this indication
SHR-6209Phase 3Small moleculeCDK4not yet gradedNo reviewed efficacy summary in this indication
Sirolimus For Injection (Albumin-Bound)Phase 3Small moleculemTOR (mechanistic target of rapamycin complex 1), via FKBP-12not yet gradedNo reviewed efficacy summary in this indication
TaragarestrantPhase 3Small moleculeEstrogen receptornot yet gradedNo reviewed efficacy summary in this indication
TersolisibPhase 3Small moleculePI3K-alpha (mutant-selective, allosteric)not yet gradedNo reviewed efficacy summary in this indication
Tibremciclib (Kangmeina)Phase 3Small moleculeCDK4 and CDK6Partial signal
NCT05433480: Investigator-assessed PFS: tibremciclib plus fulvestrant median 16.5 months (95% CI 12.8 to 16.6) vs placebo plus fulvestrant 5.6 months (95% CI 4.5 to 9.2); HR 0.37 (95% CI 0.27 to 0.52), P<.001
Trastuzumab PamirtecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
Trastuzumab RezetecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication

Large race: only the 62 furthest-along competitors are listed; 45 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(17 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Zoledronic acid to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
December 2026 (2)
Phase 1Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Myelodysplastic Syndrome …RecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12 · NCT02508038 · CT.gov ↗
What to watch
Phase 1With MSS/pMMR Advanced, Platinum-resistant Ovarian CancerRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-31 · NCT06513624 · CT.gov ↗
What to watch
2027 (8)
February 2027 (5)
Phase 4Osteoporosis, PostmenopausalActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-02-01 · NCT05655013 · CT.gov ↗
What to watch
Phase 1Epithelial Ovarian, Fallopian Tube, Primary Peritoneal CancerActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-02-02 · NCT05053750 · CT.gov ↗
What to watch
Early phase / not applicableControlled Type 2 Diabetic Patients With PeriodontitisNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-02-07 · NCT07753317 · CT.gov ↗
What to watch
Phase 1/2Congenital Dyserythropoietic Anemia (CDA)RecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-02-25 · NCT07471516 · CT.gov ↗
What to watch
Phase 2Critical Illness, OsteoporosisRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-02-28 · NCT04608630 · CT.gov ↗
What to watch
April 2027 (1)
Phase 3Giant Cell Tumor of BoneRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-04 · NCT03295981 · CT.gov ↗
What to watch
May 2027 (1)
Phase 3Imaging Examination Shows at Least One Site With Bone Metastases From Soild TumorsNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-05-31 · NCT06221072 · CT.gov ↗
What to watch
August 2027 (1)
Phase 1Chronic Kidney Disease, Osteoporosis, DialysisNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-08-15 · NCT07741136 · CT.gov ↗
What to watch
2028 (3)
January 2028 (1)
Phase 1Hematopoietic Stem Cell TransplantationRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-01 · NCT07375290 · CT.gov ↗
What to watch
February 2028 (1)
Phase 4Primary HyperparathyroidismRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-02-01 · NCT06859580 · CT.gov ↗
What to watch
December 2028 (1)
Phase 4HIV Infected Individuals, OsteopeniaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-12-01 · NCT06762730 · CT.gov ↗
What to watch
2029 (1)
March 2029 (1)
Phase 2Osteomyelitis ChronicNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2029-03-15 · NCT07668583 · CT.gov ↗
What to watch
2030 (3)
February 2030 (1)
Phase 1/2Neuroblastoma, Rhabdomyosarcoma, Synovial Sarcoma, Peripheral Nerve Sheath Tumors, Clear Cell Sarcoma, Alveolar Soft Part Sarcoma …RecruitingStudy of the molecule, not a specific product
Est. primary completion 2030-02 · NCT06625190 · CT.gov ↗
What to watch
August 2030 (1)
Phase 4OsteoporosisRecruitingStudy of the molecule, not a specific product
Est. primary completion 2030-08-31 · NCT06059222 · CT.gov ↗
What to watch
October 2030 (1)
Phase 4Postmenopausal OsteoporosisRecruitingStudy of the molecule, not a specific product
Est. primary completion 2030-10 · NCT06767150 · CT.gov ↗
What to watch

See the full readout calendar ↗